DiaMedica Therapeutics
DMAC
38 hedge funds and large institutions have $11.3M invested in DiaMedica Therapeutics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 4
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
6% more funds holding
Funds holding: 36 → 38 (+2)
3% more capital invested
Capital invested by funds: $11M → $11.3M (+$289K)
0.76% less ownership
Funds ownership: 11.2% → 10.44% (-0.76%)
77% less call options, than puts
Call options by funds: $6K | Put options by funds: $26K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$367K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$109K |
| 3 |
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture
Dallas,
Texas
|
+$74.2K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$68.3K |
| 5 |
Jane Street
New York
|
+$58.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$548K |
| 2 |
ACM
Altium Capital Management
New York
|
-$515K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$69K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$1.33K |
| 5 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
-$1.24K |
DMAC Hedge Fund Activity: Q4 2023 in Review
38 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q4 2023, worth a combined $11.3M — up 2.6% from $11M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new DMAC positions and 3 closed out — a net gain of 3 holders — while 12 added to existing stakes and 4 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $367K. The largest seller was EAM Investors, exiting entirely with an estimated $548K sold.
- 38 institutional investors held DiaMedica Therapeutics (DMAC) as of Q4 2023, up from 36 in Q3 2023.
- Funds reported $11.3M of DiaMedica Therapeutics stock for Q4 2023, up 2.6% quarter-over-quarter.
- 6 funds opened new DiaMedica Therapeutics positions in Q4 2023 and 3 closed out, a net change of +3 holders.
- The largest DiaMedica Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $367K added.
- The largest DiaMedica Therapeutics seller in Q4 2023 was EAM Investors, an estimated $548K sold.
Based on aggregated 13F filings for Q4 2023.